Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.8K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.8K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Metabolic Risk in Childhood Brain Cancer Survivors with Childhood-Onset Growth Hormone Deficiency.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same author

Correction: Fatigue among adult survivors of childhood cancer: findings from the French Childhood Cancer Survivor Study.

Journal of cancer survivorship : research and practice·2026
Same author

TRK inhibitors in pediatric gliomas.

Neuro-oncology advances·2026
Same author

Molecular evolution of mosaic chromosome 18 copy-number alterations from gametes to hepatoblastoma.

JHEP reports : innovation in hepatology·2026
Same author

Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial.

Targeted oncology·2026
Same author

Fatigue among adult survivors of childhood cancer: findings from the French Childhood Cancer Survivor Study.

Journal of cancer survivorship : research and practice·2026

Related Experiment Video

Updated: Mar 1, 2026

Reconstruct Human Retinoblastoma In Vitro
06:52

Reconstruct Human Retinoblastoma In Vitro

Published on: October 11, 2022

1.8K

Retinoblastoma: Update on Current Management.

Nathalie Cassoux1,2, Livia Lumbroso1, Christine Levy-Gabriel1

  • 1Ocular Oncology, Institut Curie, Paris, France.

Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)
|May 31, 2017
PubMed
Summary
This summary is machine-generated.

Retinoblastoma treatment has evolved significantly, improving outcomes in developed nations but still posing challenges in emerging countries. Future strategies focus on advanced diagnostics and risk stratification to balance eye preservation with child survival.

Keywords:
managementretinoblastoma

More Related Videos

Establishment and Propagation of Human Retinoblastoma Tumors in Immune Deficient Mice
07:55

Establishment and Propagation of Human Retinoblastoma Tumors in Immune Deficient Mice

Published on: August 4, 2011

12.2K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K

Related Experiment Videos

Last Updated: Mar 1, 2026

Reconstruct Human Retinoblastoma In Vitro
06:52

Reconstruct Human Retinoblastoma In Vitro

Published on: October 11, 2022

1.8K
Establishment and Propagation of Human Retinoblastoma Tumors in Immune Deficient Mice
07:55

Establishment and Propagation of Human Retinoblastoma Tumors in Immune Deficient Mice

Published on: August 4, 2011

12.2K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K

Area of Science:

  • Pediatric Oncology
  • Ophthalmology
  • Cancer Research

Background:

  • Retinoblastoma, a rare childhood cancer, has seen survival rates improve dramatically in industrialized nations over the past century.
  • Despite advances, high mortality persists in emerging countries, highlighting global disparities in cancer care.
  • Current treatment evolution aims for eyeball preservation, but must rigorously avoid compromising the child's life by preventing metastatic recurrence.

Purpose of the Study:

  • To trace the historical evolution of retinoblastoma treatments from the early 20th century to present-day innovations.
  • To explore potential future treatment modalities for retinoblastoma.
  • To emphasize the critical balance between ocular salvage and oncological safety in retinoblastoma management.

Main Methods:

  • Historical review of retinoblastoma treatment strategies and outcomes.
  • Analysis of recent advancements in pediatric eye cancer therapy.
  • Discussion of emerging diagnostic and prognostic tools for retinoblastoma.

Main Results:

  • Significant reduction in retinoblastoma mortality in industrialized countries due to treatment advancements.
  • Persistent high mortality rates in emerging economies indicate a need for improved access and tailored treatments.
  • The shift towards eye-sparing treatments necessitates careful monitoring for metastatic disease.

Conclusions:

  • Ophthalmologists treating retinoblastoma must prioritize the child's life over eyeball preservation, avoiding any approach that increases metastatic risk.
  • Implementing new international classifications and prospective multicenter studies is crucial for better patient stratification.
  • Research into blood biomarkers for predicting micrometastasis risk could significantly enhance patient management and outcomes.